Home Overview Press Room Blog Publications For Students about us
Search

Stem Cells: Where Science, Hope and Hype Meet

by Danielle VentonKQED News
June 22nd, 2016

A human embryonic stem cell.

When stem cells burst on to the public scene 20 years ago, hand-wringing and excitement in equal measure ensued.

Scientists had known about these precursors to different types of cells since the 19th century, but it wasn’t until 1998, when researchers developed a method to derive stem cells from human embryos and grow them in the laboratory, that the excitement began to build. After discovering that these cells could transform into any kind of specialized cell in the body (a quality called “pluripotent”), the research team expressed hope stem cells could be used to aid in drug discovery or replace diseased or damaged tissue.

The outcry was swift. Though the cells were derived from the unused embryos created for in vitro fertilizationand were donated for research with informed consent, many anti-abortion groups believed using the cells was tantamount to taking human life. With this perspective in mind, President George W. Bush in 2001 banned federal funding for any studies using newly created stem cell lines.

But in 2004, Californians voted to circumvent these federal restrictions, passing Proposition 71, a bond measure that gave the state $3 billion to create a state stem cell research agency, now called the California Institute for Regenerative Medicine.

CIRM’s website reflects the early optimism over stem cells, prominently featuring the slogan,“Turning stem cells into cures.” To date, however, none of the research CIRM has funded has resulted in an approved therapy. Currently, the only widely used stem cell-based therapy is for bone marrow transplantation.

“Basically, voters were led to believe in California that stem cell therapies were miraculous cures that were right around the corner,” says David Jensen, a retired newspaper reporter, and prolific blogger who maintains the California Stem Cell Report. “But that didn’t really reflect scientific reality.” 

CIRM’s Kevin McCormack, director of public communications and patient advocate outreach, agrees that Proposition 71 advertising overpromised. “That’s something [the agency has] had to live with,” he says. “People always say, ‘You promised us cures, where are they now?’ One of the things I try to do is have people’s expectations be hopeful, but realistic.”

CIRM has around $900 million left of its $3 billion initial funding, which McCormack says will last about another five years at the current rate of spending. The agency has been under pressure the last several years to streamline the funding and research process. McCormack points to the 16 clinical trials the agency is currently funding, and a stem cell accelerator project recently announced. CIRM is also in discussion with the FDA, other stem cell organizations and patient advocacy groups to create a better system for regulating and approving therapies.

But the frustration many voters feel about CIRM may have more to do with the problematic way researchers, institutional communicators and the media talk about scientific progress in general, and stem cells in particular, than it does with the agency’s performance.

“There has always been this high-stakes, extreme rhetoric around stem cells,” says Timothy Caulfield, who teaches science and health policy at the University of Alberta. Caulfield says because stem cell research was so embattled, many spoke of its promise in hyperbolic terms.

“People had to make bold statements about the future of stem cells in order to counteract those that wanted to have strict laws to stop it. So you have to say, ‘This is going to save lives. This is going to cure a variety of diseases.’ Right from the beginning, the late ’90s, you have that language appearing in the popular press.” 

Caulfield, who co-authored an opinion piece in Science titled “Confronting stem cell hype,” and who researches the way scientific claimsare exaggeratedsays that even as the debate over the ethics of stem cell research has waned, a hyperbole hangover lingers. “We’re still seeing all this breakthrough miracle language,” he says.  

Some in the scientific establishment are trying to tone things down. In May, the International Society for Stem Cell Research released updated guidelines for how stem cell science should be conducted, as well as how it should be communicated.

That effort may be facing long odds. There are systemic problems, Caulfield says, in how research is funded and promoted. He asserts that every step in the process of disseminating scientific information is driven by incentives to make progress sound a little rosier than reality.

“It’s really the invisible hand of hype,” he says. “In most cases these pressures are largely unconscious — whether you’re talking about the media, the researchers, the institutions or the funding agencies.”

New and Improved Studies

Scientists are of course excited about their work and are under pressure from their institutions to publish. Abstracts (summaries placed at the beginning of research papers) have been shown to frequently feature a little extra oomph in promoting the research that follows. One study found that scientific abstracts containing eye-catching words like “innovative,” “unprecedented,” and “robust” were up nearly 900% in 2014 compared to 1974.

The press releases announcing researchers’ findings go even further.

Caulfield says journalists, for lack of space or time, often leave out critical information like a study’s small size, the difference between correlation and causation, and researchers’ conflicts of interest. What results are stripped-down stories omitting important caveats, and that can produce more certainty than merited.

Such exaggerations make the stem cell field vulnerable to exploitation. “Once you move to the market the hype is brought up further,” says Caulfield. For example, some clinics offer unproven and even dangerous stem cell treatments for everything from baldness to Lou Gehrig’s disease. 

What to do? Patients and health care writers and journalists should cultivate a healthy skepticism, for one. One source for a critical look at reported health studies is the watchdog site Health News Review, where an ABC News story reporting on stem cell therapy for muscular dystrophy was recently criticized for potentially inducing false hope in those who have the disease.

Individuals with this type of serious condition often feel desperate and short on time.

“I get calls every single day from people asking me if we have clinical trials for all manner of different diseases,” says McCormack at CIRM. “Today it was a person calling about his mother who has Alzheimer’s.” He notes that CIRM is not currently running any trials for the disease.

“There is this sense of frustration,” McCormack says. “They’ve been hearing about this work for 10 years and, why is it no nearer to being able to help people?”

The answer is that medical science works best when it proceeds cautiously, he says. And, undeniably, progress is being made in stem cell science, even if it seems slow. A search for stem cell clinical trials at ClinicalTrials.gov, for example, brings up 1,545 open trials, which are a necessary precursor to approval by the FDA.

Researchers like Michael Rudnicki, director of the Regenerative Medicine Program and the Sprott Centre for Stem Cell Research in Ottawa, believe that an age of new stem cell therapies does lie ahead.

“We are starting to see stem cells applications getting into the clinic at an increasingly rapid rate,” Rudnicki says. “I think we’re at a tipping point, things are simply starting to come of age.”

Image via Flickr/Wellcome Images



This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of biotechnology and public policy issues. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.copyright.gov/title17/92chap1.html#107. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760